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IFN-γ stimulated dental follicle mesenchymal stem cells regulate activated lymphocyte
response in rheumatoid arthritis patients in vitro
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Background/aim: Multipotent mesenchymal stem cells (MSCs) have been investigated in autoimmune diseases such as rheumatoid
arthritis (RA) due to their immunomodulatory and regenerative properties. In this study, their immunosuppressive effects on peripheral
blood mononuclear cells (PBMC) of RA patients were studied.
Materials and methods: Dental follicle stem cells (DFSCs) were isolated from follicle tissue in the orofacial region. Characterization
and multipotency analyses were performed. Lymphocytes were isolated from peripheral venous blood of RA patients (n = 5) and
healthy individuals (n = 5). DFSCs were preincubated with IFN-γ for 48 h. PBMCs of RA patients and healthy individuals were
separately cultured with or without DFSCs for 72 h. After culture period, lymphocyte proliferation and viability, the frequency of CD4+
CD25+FoxP3+ T regulatory cells, IL-10 and TNF-α levels in the culture supernatants were measured via flow cytometry.
Results: Our results demonstrated that DFSCs suppressed proliferation of T lymphocytes by increasing the number of FoxP3 expressing
CD4+CD25+ T regulatory cells and suppressed lymphocyte apoptosis in RA patients. Also, DFSCs reduced TNF-α cytokine secretion
and upregulated IL-10 secreting cells.
Conclusions: Such cells could potentially be a source for future immunomodulatory treatments of RA patients.
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1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by pain and stiffness of the joints
and inflammation of the synovial membrane that may
cause severe morbidity and mortality. Although the
precise etiology of RA remains unclear, autoreactive T
cells and inflammatory cytokines such as TNF-α, IL1β, and IL-6 have a significant role in the pathogenesis
of RA. Synovial inflammation and joint destruction are
induced by the production of matrix metalloproteinase
as well as the maturation and activation of osteoclasts
(1–3). Mechanisms of joint destruction appear to be, at
least in part, uncoupled from inflammation (4). Therefore,
suppression of inflammation may not be sufficient to stop
RA disease progression.
Biologic therapies inhibiting inflammation reduce
the clinical symptoms and increase complete remission.
Currently available biological agents for the management
of RA are anticytokines (anti-TNFα, anti-IL-1β, or antiIL-6), anticell therapies (anti-B cell, CTLA-4Ig), and

signal inhibitors (JAK inhibitors). Although biologics are
mostly effective, there is still an unmet clinical need for
new approaches as patients’ refractory to current biologics
are at risk of further cartilage and joint damage. Therefore,
novel treatment strategies for both antiinflammation and
bone regeneration are required (5–7).
Mesenchymal stem cells (MSCs) are multipotent cells
that can be achieved from many tissues like bone marrow,
adipose and dental tissues, and are able to differentiate
into various lineages of cell types (8). MSCs originating
from the orofacial region are easy to access and isolate
(9). In addition to their differentiation potential and tissue
regeneration, dental MSCs have been reported to regulate
immune responses in autoimmune diseases. MSCs have
potent immunosuppressive and antiinflammatory effects
through direct cell-cell contact or by secreting soluble
factors such as indoleamine 2,3-dioxygenase, TGF-β,
prostaglandin E2 (PGE2), and nitric oxide synthase, and
inhibit the activation, proliferation, and function of a
variety of immune cells including T cells, B cells, natural
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killer (NK) cells, and antigen-presenting cells. Besides,
they have the potential for clinical application in the repair
of damaged tissue. FoxP3 expressing Treg cells play a
significant role in controlling autoimmune responses and
maintaining peripheral tolerance (10–11). Deficiencies
in Treg cell function have been identified in autoimmune
diseases including RA (12), psoriasis (13), and myasthenia
gravis (14). Interferon-gamma (IFN-γ) is known to
enhance the immunosuppressive properties of MSC.
IFN-γ preactivated MSCs directly or indirectly regulate T
cell responses by increasing or inducing MSC inhibitory
factors (15).
In some studies of RA, patients data suggested that
bone marrow or adipose-derived MSCs have the ability
to regulate the immune functions by reducing the
inflammatory Th1/Th17 responses and enhancing the
protective regulatory T cell response (16,17). The recent
evidence that MSCs with the capacity to differentiate into
cartilage are available in joint tissues gives an opportunity
for the therapeutic use of these cells (18). However, it is
not exactly known whether MSCs have inflammatory or
antiinflammatory effect in RA.
In the present study, we investigated the
immunomodulatory effects of DFSCs on T cells in RA
patients in vitro. Cytokine levels were also investigated to
explain the regulatory effects of DFSCs on mononuclear
cells in RA. This study provides basic data for further
detailed investigation of DFSCs as a new and effective
source for cell-based therapies in inflammatory disease.
2. Materials and methods
2.1. Ethics
This study was approved by the Ethics Committee of the
Marmara University School of Medicine, Istanbul, Turkey
(Protocol No: 09.2015.196/70737436–050.06.04). Written
informed consent was obtained from all patients.
2.2. Isolation, characterization, and differentiation potential of DFSCs
Isolation of mesenchymal stem cells was performed as
previously described (16). Briefly, dental follicle tissues
were cut into 0.5 mm pieces and enzymatically digested
with 3 mg/mL collagenase type I (Gibco, USA) for 45
min at 37 °C. Inactivation of the enzyme cell pellets
was transferred to T-25 flasks containing 5 × 103 cells/
cm2 and incubated at 5% CO2 atmosphere at 37 °C in
culture medium composed of DMEM, 10% FBS, and 1%
penicillin/streptomycin. Stem cells were detached with
0.25% trypsin-EDTA (Gibco, USA) and passaged until the
third passage. Third passage cells were analyzed for surface
antigen expressions. Cells were incubated with antibodies
of positive markers for mesenchymal stem cells of human
CD29, CD73, CD105, CD146, and negative markers CD14,
CD34, CD20, and HLA-DR (BD Biosciences, USA) for
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15 min at room temperature in the dark. Flow cytometry
results were analyzed using BD FACS Calibur.
Osteogenic, adipogenic, and chondrogenic stimulants
(StemPro) were added separately into seeded cell cultures
to induce the differentiation process. The differentiation
assay was performed in 6-well plates (5 × 104 cell/well);
differentiation media were prepared according to the
manufacturer’s instructions and changed 3 times per week.
After 14 days, the osteocytes, adipocytes, and chondrocytes
were stained with alizarin red, oil red O, and alcian blue,
respectively, and after 21 days the cell types were evaluated
under a microscope.
2.3. Isolation of peripheral blood mononuclear cells
(PBMC)
Peripheral blood was collected from 6 RA patients (2 men
and 4 women). All patients met the American College of
Rheumatology 1987 revised classification criteria for RA,
and disease duration of patients was a minimum of 24
months. They had active disease and were not receiving
corticosteroids and disease modifying antirheumatic drugs
at the time of sample collection. In addition, peripheral
blood was collected from 6 healthy individuals (3 men
and 3 women) without an autoimmune or inflammatory
disease as control group.
PBMC were isolated from heparinized peripheral
blood samples by using Ficoll-Paque (GE Healthcare
Bio-Sciences) density gradient solution, as previously
described (14). The cells were cultured in RPMI (Gibco,
USA) supplemented with 10% FBS and 1% penicillin/
streptomycin with the addition of stimulatory agents.
2.4. Coculture of PBMC with DFSCs
DFSCs (5 × 104/well in a 48-well plate) were plated 48
h prior to the addition of tenfold of lymphocytes in
the culture medium. DFSCs and PBMCs (1:10) were
cocultured for 72 h. The cultures were stimulated by using
0.5 µg/mL of CDmix (anti-CD3 and anti-CD28), IFN-𝛾
(0.5 μg/mL, Millipore, CA, USA), Derp 1 (0.5 μg/mL), or
Dexamethasone (10–4 M). Then, lymphocyte proliferation
(carboxyfluorescein succinimidyl ester, CFSE), apoptosis
(Annexin V/PI), CD4+CD25+FoxP3+ Treg ratios from
PBMC, and cytokine levels from culture supernatants
were analyzed via flow cytometry.
2.5. CFSE assay and evaluation of lymphocyte proliferation
The proliferation of lymphocytes was evaluated by labeling
PBMC with 10 μM carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen, USA). The lymphocytes were cultured
unstimulated or stimulated with anti-CD3/anti-CD28
(CDmix) in the presence and absence of DFSCs and
analyzed for CFSE signaling via flow cytometry (FACS
Calibur).
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2.6. Detection of apoptosis of the lymphocytes by Annexin V/PI
After 72 h of incubation period, the apoptosis ratio of
lymphocytes was quantified by using the Annexin V/PI
kit (eBiosciences, USA) according to the manufacturer’s
instructions. Flow cytometric analysis was performed by
staining PBMC with anti-CD3 and anti-CD4 antibodies
for Annexin V/PI detection.
2.7. CD4+CD25+FoxP3+ Tregulatory cell frequency
After 72 h of coculture, the CD4+CD25+FoxP3+ Treg
lymphocytes were quantified using Human FoxP3 Buffer
Kit (eBioscience, USA). The frequency of FoxP3 expressing
regulatory T cells (CD4+CD25+FoxP3+) was analyzed in the
cultured lymphocytes via flow cytometry. The kit included
antihuman CD4 (FITC), antihuman CD25 (APC), and
antihuman FoxP3 (PE) (eBioscience, USA).
2.8. Analysis of cytokine expression profiles
Supernatant from cultures was collected and stored at –80
°C until assayed. Samples were measured and analyzed
for TNF-α and IL-10 cytokine levels by Cytokine Bead
Array (CBA) kit (BD Biosciences, USA) according to the
manufacturer’s protocol. Briefly, all the CBA kit contents
and samples should be at room temperature for at least
15 min. Fifty μL of culture supernatants, 50 μL of capture
beads, and 50 μL of detection reagent were added and
incubated for 3 h. After incubation, samples were washed
twice with cold PBS. Samples were acquired in a FACS
Calibur flow cytometer (BD Biosciences) and analyzed
using the FCAP Array v1.0.1 software (Soft Flow Inc.).
Results were expressed as picograms per milliliter.
2.9. Statistical analysis
The statistical analysis was achieved by using GraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA). Oneway analysis of variance (ANOVA) with Tukey’s multiple
comparisons was used for multigroup comparisons,
and a two-tailed unpaired Student’s t-test was used for
comparisons between two groups; a P value of < 0.05 was
considered statistically significant.
3. Results
3.1. Isolation, characterization, and differentiation of
DFSCs
The MSCs were isolated from dental follicle tissues. Their
proliferation gradually formed small colonies in 3 days.
The MSCs reached 70% confluency in the primary culture
7 days after plating for the first passage. Most of the MSCs
exhibited fibroblast-like morphology at the P3 passage
(Figure 1a).
The MSCs were analyzed via flow cytometry. These
cells exhibited positive staining for CD29, CD90, CD 146,
CD73, and CD106, but were negative for CD34, CD45,
CD14, CD28, and CD25 (Figure 1b).

The MSCs differentiated into osteocytes, adipocytes,
and chondrocytes. First, the osteogenic differentiation
capability was investigated in vitro during a 28-day
culture period in osteogenic induction medium. The
MSCs were stained with alizarin red and the cells formed
calcified bone nodule structures. Next, in vitro adipogenic
differentiation capability was assessed by culturing the
cells in adipogenic induction medium and staining with
oil red O. Intracellular lipid droplets were observed in
these cells. Chondrogenic differentiation capability was
investigated in vitro following 14-day culture period in
chondrogenic induction medium and cell differentiation
into chondrocytes was confirmed with alcian blue staining
that exhibited intracellular proteoglycans in those cells
(Figure 1c).
3.2. DFSCs decreased proliferative response of lymphocytes in RA patients
We investigated the immunomodulatory effect of T
lymphocytes in RA and healthy controls by CFSE
cell labeling. Lymphocyte proliferation capacity was
significantly higher in RA patients (55.95 ± 3.12) compared
to healthy controls (30.98 ± 1.72; P < 0.001). DFSCs
significantly suppressed the proliferation of lymphocytes
in the cocultures of CDmix stimulated PBMCs in RA
patients when compared with PBMC cultures alone (P <
0.001). IFN-γ stimulation of DFSCs further suppressed
the lymphocyte proliferation in RA patients (12.43 ±
2.19) when compared with PBMC cultures alone (55.95 ±
3.12; P < 0.0001). In the presence of DFSCs, lymphocyte
proliferation of healthy controls tended to decrease, but the
difference was not significant (P > 0.05). IFN-γ stimulated
DFSCs significantly suppressed lymphocyte proliferation
capacity in healthy controls (12.39 ± 2.19) compared to
PBMC cultures alone (28.17 ± 2.60; P < 0.01) (Figure 2).
3.3. DFSCs enhance the ratio of viable lymphocytes in
RA patients
To investigate the effect of DFSCs on cell viability of
lymphocytes, Annexin V-/PI- ratio is determined on
the surface of lymphocytes. The viable lymphocyte ratio
stimulated with CDmix was lower in RA patients (57.57
± 2.36) compared to healthy controls (68.64 ± 2.08, P ˂
0.01). DFSCs increased the cell viability of T lymphocytes
in RA (74.18 ± 2.23) and healthy groups (79.35 ± 1.19),
which was more prominent in RA patients compared to
healthy controls (P ˂ 0.001 and P ˂ 0.01, respectively).
IFN-γ stimulated DFSCs also increased antiapoptotic
effect of DFSCs in RA patients (P ˂ 0.0001) (Figure 3).
3.4. DFSCs increased CD4+CD25+FoxP3+ Treg cell ratio
in RA patients
We studied the effects of DFSCs on the Treg cell ratio in
RA patients’ PBMCs. CD4+CD25+FoxP3+ Treg cell ratio
was significantly lower in unstimulated, CDmix stimulated
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Figure 1. Morphological appearance, characterization, and multipotency of DFSCs. A) Morphology of DFSCs in P0, P1, P2, and P3
(magnification = 10×). B) Representative flow cytometry analysis of positive surface markers CD105, CD146, CD90, CD73, CD29, and
negative surface markers CD25, CD28, CD14, CD45, CD34 for DFSCs at third passages. C) alizarin red staining of osteogenic induced
DFSCs, oil red staining of adipogenic induced DFSCs, Alcian blue staining of chondrogenic induced DFSCs; scale bar = 1000 µm.

PBMC cultures compared to healthy individuals (P < 0.05).
DFSCs increased the CD4+CD25+FoxP3+ Treg cell ratio
significantly in unstimulated, CDmix cocultures compared
to PBMC cultures alone in both RA patients and healthy
individuals (P < 0.001 and P < 0.05, respectively). IFN-γ
stimulation of DFSCs further increased FoxP3 expressing
Treg cells in RA patients (P < 0.0001). This data suggest
that DFSCs can regulate immune responses by increasing
the amount of FoxP3 expressing Treg cells (Figure 4).
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3.5. DFSCs regulated inflammatory response by decreasing TNF-α and increasing IL-10 levels in RA patients
To assess the immunomodulatory effects of DFSCs on
lymphocyte phenotypes we evaluated proinflammatory
and antiinflammatory cytokine levels in PBMCs of RA
patients. Both cytokines were analyzed in PBMC cultures
in the presence and absence of DFSCs. PBMC cultures
of RA patients showed high levels of TNF-α, which is
the signature cytokine of inflammatory responses in
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Figure 2. Inhibitory effect of DFSCs on the proliferation of lymphocytes as detected by CFSE. A) After 72 h of coculture, effect of DFSCs
on the proliferation of lymphocytes displayed by flow cytometry. IFN-g stimulated DFSCs suppressed lymphocyte proliferation. B)
Inhibitory effect of DFSCs on the proliferation of lymphocytes displayed statistically. *P < 0.05, **P < 0.01, ****P < 0.0001. Results are
shown as mean ± SD.

lymphocytes, and lower levels of IL-10 compared to
healthy individuals (P < 0.0001 and P < 0.05, respectively).
TNF-α levels were significantly decreased (P < 0.001) and
IL-10 levels were significantly increased (P < 0.01) when

cultured with DFSCs compared to PBMC cultures alone in
RA patients, whereas no significant change in cocultures
was observed in TNF-α levels in healthy individuals (P
˃ 0.05). IFN-γ stimulated cocultures decreased TNF-α
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Figure 3. Cell survival analysis of T lymphocytes. A) Lymphocytes were stained with Annexin V (PE) and PI in order to analyze cell
survival and apoptotic ratio of lymphocytes. Lower left quadrants (Annexin-/PI-) were evaluated for cell survival ratio. B) In statistical
analysis, cell survival ratio of PBMC increased with DFSCs in RA and healthy control groups, and it is statistically significant (****P <
0.0001, P < 0.01, respectively). IFN-g enhanced antiapoptotic characteristic of DFSCs, especially in RA patients. *P < 0.05, **P < 0.01,
****P < 0.0001. Results are shown as mean ± SD.

levels compared to cocultures without IFN-γ stimulation
in RA patients (P < 0.0001). IFN-γ stimulated cocultures
also increased IL-10 levels compared to cocultures without
IFN-γ stimulation in RA patients (P < 0.0001) (Figure 5).
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4. Discussion
In this study, we showed that DFSCs suppressed the
proliferation of activated lymphocytes of RA patients
by increasing the frequency of CD4+CD25+Foxp3+ T
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Figure 4. CD4+CD25+Foxp3+ analysis of T lymphocytes. A) Lymphocytes were stained with CD4+ (FITC), CD25+ (APC), and Foxp3+
(PE) in order to analyze the frequency of Treg cells. CD4+Foxp3+ cells were analyzed from CD25+ cells. B) In statistical analysis,
CD4+ CD25+Foxp3+ ratio of PBMC increased with DFSCs in RA and healthy control groups, and it is statistically significant (***P <
0.001, P < 0.05, respectively). IFN-g stimulated DFSCs enhanced frequency of CD4+CD25+Foxp3+ cell ratio, especially in RA patients,
compared to unstimulated DFSCs. *P < 0.05, ***P < 0.001, ****P < 0.0001. Results are shown as mean ± SD.
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Figure 5. Cytokine levels in culture supernatants. TNF-α level was high and IL-10 levels were low in CDmix stimulated PBMC cultures
of RA patients compared to healthy individuals. DFSCs significantly decreased TNF-α levels in CDmix (P < 0.001) and IFN-g stimulated
(P < 0.0001) cocultures in RA patients. DFSCs increased IL-10 levels in CDmix (P < 0.01) and IFN-g stimulated (P < 0.0001) cocultures
in RA patients. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Results are shown as mean ± SD.

regulatory cells. In addition, a significant reduction of
PBMC apoptosis was observed in the presence of DFSCs
in RA patients.
Rheumatoid arthritis is a chronic autoimmune disease
that causes progressive articular damage and functional
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loss of joints. The development of new antiinflammatory
drugs and kinase inhibitors in the past two decades has
substantially improved clinical outcomes. Cytokine
inhibitors have definitively proven the critical role of
TNF-α and IL-6 in disease pathogenesis. Many patients
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can achieve long remissions if the disease is recognized
and treated promptly and continuously; however, some
individuals do not respond adequately to treatment.
Nonetheless, no therapy is curative and clinical remission
does not necessarily correspond to nonprogression of joint
damage.
In this context, mesenchymal stem cells (MSCs) are
potential candidates for repairing damaged tissues in
joint disorders, including RA. Additionally, MSCs with
the ability to differentiate into cartilage are present in
joint tissues and raise an opportunity for therapeutic
interventions via targeting intrinsic repair mechanisms.
In addition to the ability to differentiate into cartilage or
other tissue cells, MSCs can interact with the immune
system and play an active role in the regulation of arthritis
and progression of joint damage.
To examine the T cell activation in RA pathogenesis,
we investigated the proliferative responses of T cells in
the presence of DFSCs. According to our results, DFSCs
decrease pathogenic T cell responses in RA patients. In
agreement with our data, MSCs isolated from different
tissues (bone marrow or adipose tissue) were previously
shown to reduce inflammatory and T cell responses and
induce regulatory T cells in vitro in RA (16,17). However,
an important issue for clinical translation of MSCs for RA
treatment is the requirement of large number of cells for
infusion during therapeutic uses. However, recent studies
demonstrated that large amounts of DFSCs can be easily
obtained from follicle tissues of healthy donors and rapidly
expanded in vitro to generate a clinically effective dosage.
A key role of aberrant pathways of T cell activation
in the initiation and/or progression of RA is suggested.
Previous studies showed that MSCs not only show
immunomodulatory capacity, but also have antiapoptotic
properties that cause supporting activity toward different
cell types under resting conditions (19,20). In our previous

study, we showed that DFSCs decreased the expression
of apoptosis-related ligand and receptors on healthy
individuals’ lymphocytes (21). In the present study, we
investigated the effects of DFSCs on cell survival of T
cells of RA patients. Lymphocyte viability ratio was low
in CDmix stimulated PBMC cultures of RA patients,
while it was high in healthy controls. DFSCs significantly
increased T cell viability and decreased apoptosis in CDmix
stimulated cocultures in RA patients. IFN-g stimulated
DFSCs further increased the viability of T lymphocytes in
RA patients. DFSCs also had an antiapoptotic effect on T
cells of RA patients, and IFN-g stimulation increased this
effect of DFSCs.
Treg cells play a central role in controlling autoimmunity,
and their dysfunction leads to immune activation. A
number of studies suggested that stem cell or biological
therapies induce a potent population of CD4+CD25+
Treg cells in patients with RA (22,23). The current study
revealed that low levels of CD4+CD25+Foxp3+ regulatory
T lymphocyte population were increased with DFSCs
in RA patients, associated with elevated IL-10. IFN-g
stimulated DFSCs further enhanced CD4+CD25+Foxp3+
regulatory T lymphocyte frequency. Therefore, induction
of CD4+CD25+Foxp3+ T regulatory cells could significantly
contribute to the suppressive activity of DFSCs on RA T
cells.
As a critical cytokine driving inflammation, TNF-α is
a key therapeutic target for RA treatment (24). A previous
study demonstrated that conditioned medium MSC
treatment prevents TNF-α rise in sera from arthritic mice
while it increased IL-10 levels (25). In accordance with
this data, DFSCs suppressed the expression of TNF-α
levels and increased IL-10 expression in RA patients
in our study. IFN-g stimulated DFSCs further enhanced
immunosuppressive effects on cytokine levels in RA
patients.
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